LC/MS/MS is a mature technology in Bioanalysis and is often called a commodity. This may be true as it is available in many laboratories around the world. However, with today’s complex new modalities, highly challenging small molecules, peptides, and oligonucleotides, the challenges in developing LC/MS/MS assays are greater than ever. At Celerion, we’ve been doing LC/MS/MS analysis in our laboratories since 1992. We have a long history of innovations and experience with challenging projects. For instance, we have performed bioanalysis of peptides and oligonucleotides for over 20 years. The complex small molecules such as protein degraders and biomarkers often require close collaboration with our on-site clinics for proper sample collection or our LBA and Flow Cytometry teams for associated biomarker analysis. In the case of ADC’s you get all of your complex bioanalysis under one roof with one set of management. Even the traditional small molecules are smaller, stickier, less stable, and nonpolar. All challenges that a lab with experience must address. Learn more about Celerion's Bioanalytical Services: https://lnkd.in/e94Jchx #Bioanalysis #LCMSMS #Peptides #Oligonucleotides #SmallMolecules #DrugDevelopment #PharmaResearch
Celerion’s Post
More Relevant Posts
-
The complex small molecules, such as protein degraders and biomarkers, often require close collaboration with our on-site clinics for proper sample collection or our LBA and Flow Cytometry teams for associated biomarker analysis. In the case of ADC’s you get all of your complex bioanalysis under one roof with one set of management.
LC-MS/MS is a mature technology in Bioanalysis and is often called a commodity. This may be true as it is available in many laboratories around the world. However, with today’s complex new modalities, highly challenging small molecules, peptides, and oligonucleotides, the challenges in developing LC-MS/MS assays are greater than ever. At Celerion, we’ve been doing LC-MS/MS analysis in our laboratories since 1992. We have a long history of innovations and experience with challenging projects. For instance, we have performed bioanalysis of peptides and oligonucleotides for over 20 years. The complex small molecules such as protein degraders and biomarkers often require close collaboration with our on-site clinics for proper sample collection or our LBA and Flow Cytometry teams for associated biomarker analysis. In the case of ADC’s you get all of your complex bioanalysis under one roof with one set of management. Even the traditional small molecules are smaller, stickier, less stable, and nonpolar. All challenges that a lab with experience must address. Learn more about Celerion's Bioanalytical Services: https://lnkd.in/e94Jchx #Bioanalysis #LCMSMS #Peptides #Oligonucleotides #SmallMolecules #DrugDevelopment #PharmaResearch
-
-
Our Bioanalysis Showdown series this summer comparing LBA and Hybrid LC-MS/MS has wrapped up after 11 episodes! Throughout the series, Dawn Dufield, PhD, and Dominic Warrino, PhD, compared two key bioanalytical approaches: Ligand Binding Assays (LBA) and Hybrid LC-MS/MS and shared insights and tips to help you choose the right approach for your drug development projects. Before posting each video, we asked for your thoughts, and here’s a recap in numbers 🔢 A reminder of all the topics we covered: 1) What makes a great bioanalytical CRO? 2) LBA vs. Hybrid LC-MS/MS: Key benefits for large molecule analysis 3) What is Hybrid LC-MS/MS? 4) Hybrid LC-MS/MS insights: Emerging as an equal partner to LBA? 5) Unique advantages of each approach 6) Time and cost comparison between LBA and Hybrid LC-MS/MS 7) Versatility and sensitivity for biomarker quantification, especially in complex matrices 8) Decision-making process for choosing between LBA and Hybrid LC-MS/MS 9) Real-world examples of platform switching and using both approaches together, especially for Antibody-Drug Conjugates (ADCs) 10) The benefits of housing all services in one facility for flexibility and collaboration 11) Future trends: Will LBA remain dominant, or will Hybrid LC-MS/MS take over? If you missed the series, no worries! You can watch all the videos here: https://lnkd.in/dxnfaZuq #Bioanalysis #BioanalysisShowdown #LBA #HybridLCMS
-
Join us on July 31st for our webinar to learn how the Newomics platform accelerates the direct mass analysis of ADCs.
Rachel Shi, PhD from Genentech, joins us for our next webinar: “Characterizing Antibody-Drug Conjugates with Charge Detection Mass Spectrometry,” on Wednesday, July 31st at 10 AM PT. Visit the link to read the speaker abstract and register to attend! https://lnkd.in/gA7zW8nj
-
Join Prof. Johan Gabrielsson and Dr. Bernd Wendt for a new case study analyzing acute and repeated dosing of a monoclonal antibody (mAb) using literature data, followed by an exploration of pharmacologically relevant questions. 🗓️ 𝗗𝗮𝘁𝗲: June 26 🕒 𝗧𝗶𝗺𝗲: 10 AM ET 📚 𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ・Insights from the 6th edition of the standard book "Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications." ・Simulation of new synthetic population data. ・Extended pharmacological reasoning to calculate in vivo potency (IC50), covering binding properties, target turnover, and complex kinetics. ・Demonstration of pivotal pharmacological target properties. 🔍 𝗪𝗵𝘆 𝗔𝘁𝘁𝗲𝗻𝗱? ・Discover how new expressions of in vivo potency offer robust parameters for predicting exposures and doses across different individuals and species. 🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗡𝗼𝘄: https://ow.ly/WGGp50S904v #Pharmacokinetics #Pharmacodynamics #PKPD
-
-
How do fragments serve as effective starting points for discovering molecular glues? Discover our Fragment Library and HTS collections, offering versatility across different target classes. This poster highlights recent efforts to address challenging therapeutic target classes. There’s been a rise in drug targets involving biomolecular complex interactions, such as induced proximity therapeutics and nucleic acid-binding proteins. A biophysical approach using fragments is ideal for generating medicinal chemistry starting points in such complex scenarios. Learn more from Dr Steve Young (VP of Business Development) and Dr Hiroki Wada (Business Development Manager) at the EFMC-ACSMEDI MedChem Frontiers in Utrecht, April 8-11. Can’t make the event? Download our digital poster: https://lnkd.in/epRp2yEa #medicinalchemistry #fragmentbaseddrugdiscovery #fbdd #HTS #molecularglue #drugdiscovery
-
-
Struggling with immunoassays to quantify drug-mAbs ? Why not considering LC-MS instead ? Mass spectrometry has emerged as a powerful alternative with specific analytical advantages, including: - Selective quantification of the target drug-mAb - Capability for multiple mAbs measurement within a single analysis (multiplexing) - A relatively fast, versatile and cost-effective development cycle - Stable-isotopically standards available for more accurate and robust data At Promise Proteomics, we have developed a range of solutions dedicated to therapeutic monoclonal quantification using mass spectrometry. Our goal is to facilitate and speed-up your projects. Explore our range of dedicated products: https://hubs.la/Q02zfVW20 https://hubs.la/Q02zfYkf0 Or contact us at contact@promise-proteomics.com ✉ #protein #antibody #analysis #quantification #biomarkers #research #pharma #massspectrometry #LCMS #ASCO
-
-
Here Hwang et al examins the effect of chemically modified Self-assembled micelle inhibitory RNA (SAMiRNA) has upon traditional oligonucleotide LCMS analysis 🛎Overview: SAMiRNA was developed to overcome come some of the in vivo delivery challenges that is associated with Small interfering RNA (siRNA). Where SAMiRNA comtains hydrophilic and hydrophobic groups at both ends of a sense strand, forming a spherical nanostructure that enhances the in vivo delivery efficiency. 🎯 Summary: With their LCMS based assay Hwang et al observed the peak of the SAMiRNA duplex contained signals from the duplex, the antisense, and the sense, probably due to duplex denaturation during the MS ionization process. Hwang et al belives their analysis will provide useful insights to futher SAMiRNA anytical development. https://lnkd.in/eTt6FYPY #massspectrometry #massspec #biopharmaceuticals #bioanalytical #biotech #science #scienceandtechnology #research #chemistry #mrna #bioprocessing #chromatography #nucleotides #rnatherapeutics #oligonucleotides #biotech #LCMS
Analysis of Self-Assembled Micelle Inhibitory RNA (SAMiRNA) Drug Using Ion-Pairing Reversed-Phase Liquid Chromatography Combined with Mass Spectrometry
pubs.acs.org
-
On Day 3 of SLAS 2024 Carterra will present the ability to screen samples across the spectrum of small molecules to mAbs and up to 150,000 detailed binding interactions in a single experiment. The talk will cover the characterization of kinases, membrane proteins, and targeted protein degradation (TPD) small molecule assay design and other drug discovery workflows. The data will highlight the unique advantages of using HT-SPR real-time, label-free binding technology where these measurements provide for greater precision in the selection of drug candidates. 𝗧𝗵𝗲 𝗖𝗮𝗿𝘁𝗲𝗿𝗿𝗮 𝗟𝗦𝗔-𝗫𝗧®️ 𝗼𝗽𝗲𝗿𝗮𝘁𝗲𝘀 𝗮𝘁 𝘂𝗻𝗺𝗮𝘁𝗰𝗵𝗲𝗱 𝘀𝗰𝗮𝗹𝗲 𝗳𝗼𝗿 𝗯𝗶𝗻𝗱𝗶𝗻𝗴 𝗰𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻 — 𝗰𝗼𝗺𝗲 𝗵𝗲𝗮𝗿 𝗮𝗯𝗼𝘂𝘁 𝗶𝘁! #labelfree #smallmolecule #mAbs #LSAXT #Carterra #drugdiscovery #SLAS2024 #kinase #gpcr
-
-
Conference Marketing Manager at Cambridge Innovation Institute | Bioprocessing | Lithium Mining | Drug Discovery | Immunogenicity | Immuno-oncology | Biopharma | Greater Boston Area
Affinity Selection-Mass Spectrometry (ASMS) Applicability for PPI Targets with Hans-Peter Biemann from Sanofi. Affinity Selection-Mass Spectrometry (ASMS) identifies novel small molecule ligands for soluble and membrane proteins via a mass-encoded readout. We have recently applied ASMS to several challenging targets across different protein classes. These target proteins generally lack recognized druggable clefts and include PPI moieties. This presentation will review the process and status of hit ID comprising distinct externalized library HTS as well as reaching into of Sanofi’s internal collection via an intermediate virtual screening step. https://lnkd.in/ehCx6_Eg Save $150 with Discount code SPK150. #drugdiscoverychemistry
-
-
Covalent binding analysis is a crucial technique in drug discovery, aimed at comprehending how small molecules interact with target proteins by forming strong, permanent bonds. Unlike non-covalent interactions, covalent bonds offer enhanced potency and prolonged target engagement. At ICE Bioscience, we provide state-of-the-art covalent binding analysis utilizing mass spectrometry or LC-MS. This enables precise evaluation of various interactions, including KRAS mutants/EGFR mutants and drug conjugates, EGFR and SMDC (Small molecule-drug conjugates) ligand and payload release, as well as identification of covalent inhibitor binding sites (amino acids). ➡ Own Protein Library: A comprehensive repository of proteins available for a broad range of assays. ➡ Assay Establishment for New Proteins: The ability to develop and validate assays for emerging protein targets. ➡ Optimized Assay Conditions: Tailored assay conditions to ensure maximum efficiency and accuracy. ➡ High Throughput: Capacity to handle approximately 200 samples per day, facilitating rapid project advancement. #covalentbinding #massspectrometry #lcms #kras #EGFR #SMDC
